Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Annexin A2 (ANXA2) gene variants and ischemic stroke risk

Official title: Genetic Variants of Annexin A2 and Cryptogenic Stroke

Run by Centre Hospitalier Universitaire, Amiens · NCT06880107 · Data updated 2026-11-12

This project will test whether genetic differences in the annexin A2 (ANXA2) gene are linked to ischemic stroke in adults who have already experienced a completed ischemic stroke.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment240 (estimated)
SponsorCentre Hospitalier Universitaire, Amiens
Academic / other
Locations1 site (Amiens)
StatusRecruiting
StartedApril 8, 2025
Main results expectedApril 2027
Study endsApril 2027
Registry record updatedJanuary 16, 2026
Trial IDNCT06880107 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older who have had a completed ischemic stroke (neurologic deficit persisting beyond 24 hours) and can provide a blood sample are the ideal candidates.

Probably not a fit

People whose event was a transient ischemic attack, who are pregnant, or whose stroke has an already identified non-genetic cause are unlikely to benefit from this genetic analysis.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will enroll adults with a completed ischemic stroke and collect a blood sample for DNA analysis. The DNA will be genotyped to identify single nucleotide variants in the ANXA2 gene and related loci. Genotype frequencies will be compared with expected population patterns or correlated with clinical stroke features to see if specific variants are overrepresented. The work is conducted at CHRU Amiens and excludes transient ischemic attack and pregnant participants.

Why it matters

Potential benefit: If successful, identifying ANXA2 variants linked to stroke could help spot people at higher genetic risk and suggest new targets to improve fibrinolytic treatment.

How similar studies have gone: Previous human studies have linked other fibrinolysis-related genes (tPA, PAI-1) to stroke risk and animal work shows recombinant ANXA2 can aid fibrinolysis, but human data specifically linking ANXA2 variants to typical ischemic stroke remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients
* Age from 18 years old

Exclusion Criteria:

* Transient ischemic attack
* Pregnancy

Where it's running

  • CHRU Amiens
    Amiens, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.